Q4 Results Highlights: Sun Pharma earning call -US contributes 31.4% of Sun Pharma revenues

Sun Pharma earning call Live: Sun Pharma plans to launch its specialty drug Leqselvi in Q2FY26

Sun Pharma plans to launch its specialty drug Leqselvi in Q2FY26

It continues to see pressure on pricing for generic drugs in US

Sun Pharma wants to grow higher than the market growth in domestic formulation business

Q4 Results Live: Sun Pharma earning call- Expects mid to high single digit consolidated revenue.

Expects mid to high single-digit consolidated revenue. To spend approximately $100 million additionally in FY26 on new speciality products commercialisation. R&D expenditure expected to 6-8% of sales FY26

Q4 Results Live: US contributes 31.4% of Sun Pharma revenues

Growth in US business is driven by specialty portfolio including Illumya, Cequa, Winlevi offset by generics impacted by additional competition in certain products. US contributes 31.4% of Sun Pharma revenues

Q4 Results Live: Sun Pharma earning call - Net cash as on March 31 $3.1 billion

Sun Pharma earning call -Net cash as on March 31 $3.1 billion

Q4 Results Live: HFCL posts Rs 81-crore net loss

HFCL reported a net loss of Rs 81.43 crore for the fourth quarter of FY25, as against a net profit of Rs 110 crore reported in the year ago period. The firm's revenue from operations meanwhile dropped 39.6% to Rs 800.72 crore.

Along with the Q4 results, HFCL announced a dividend of Rs 0.10 per share for FY25.

Q4 Results Live: Sun Pharma net profit falls 19% to Rs 2,154 crore

Sun Pharmaceutical Industries reported a 19 percent decline in its consolidated net profit to Rs 2,153.9 crore in the fourth quarter ended March 31, 2025. The company had posted a consolidated net profit of Rs 2,658.7 crore in the year-ago period

The company's board has declared a final dividend of Rs 5.50 per share for the FY25.

Q4 Results Live: ITC clocks Rs 19,562 crore Q4 profit on exceptional gain

ITC has reported a net profit Rs 19,562 crore for the fourth quarter of FY25. This however included a one-time exceptional item of Rs 15,179 crore from discontinued operations. The firm's revenue from operations meanwhile rose to Rs 18,494 crore.

Along with the Q4 results, ITC announced a final dividend of Rs 7.85 per share for FY25

Q4 Results Live: Mamaearth-parent Honasa Consumer’s net profit falls 18% to Rs 25 crore

Mamaearth-parent Honasa Consumer reported a net profit of Rs 25 crore for the fourth quarter of the financial year 2025. This marks a fall of 18% from the Rs 30 crore net profit reported in the corresponding quarter of the previous financial year. Its revenue from operations meanwhile rose to Rs 534 crore.

Q4 Results Live: Deepak Fertilisers net profit jumps 23% to Rs 277 crore

Deepak Fertilisers reported a net profit of Rs 277 crore for the fourth quarter of the financial year 2025. This marks a jump of 23% from the Rs 251 crore net profit reported in the corresponding quarter of the previous financial year. Its revenue from operations meanwhile rose to Rs 2,667 crore.

Along with the Q4 results, the company announced a dividend of Rs 10 per equity share for FY25.

Q4 Results Live: Barbeque Nation shares tumble 5% after Q4 results

The shares of Barbeque Nation sharply fell over 5% to trade at Rs 313 apiece. This comes after the company reported a net loss of Rs 20 crore for Q4 FY25, as against Rs 1 crore loss in the year-ago period.

Q4 Results Live: Emcure Pharma shares sharply jump 5% after Q4 results

The shares of Emcure Pharmaceuticals sharply jumped over 5% to trade at Rs 1,126 apiece. This comes after the company reported a 64% YoY rise in net profit to Rs 189 crore for the fourth quarter of the financial year 2025.

Q4 Results Live: Barbeque Nation’s net loss widens to Rs 20 crore

Barbeque Nation reported a net loss of Rs 20 crore for the fourth quarter of the financial year 2025. This marks a significant rise from the Rs 1 crore net loss reported in the corresponding quarter of the previous financial year. Its revenue from operations meanwhile fell to Rs 293 crore.

Q4 Results Live: Emcure Pharma net profit soars 64% to Rs 189 crore

Emcure Pharmaceuticals reported a net profit of Rs 189 crore for the fourth quarter of the financial year 2025. This marks a jump of 64% from the Rs 115 crore net profit reported in the corresponding quarter of the previous financial year. Its revenue from operations meanwhile rose to Rs 2,116 crore.

Along with the Q4 results, the company announced a final dividend of Rs 3 per equity share for FY25.

Q4 Results Live: Mamaearth-parent Honasa Consumer shares jump 2% ahead of results

The shares of Mamaearth and The Derma Co-parent Honasa Consumer jumped nearly 2 percent to trade at Rs 275.38 apiece. The company is scheduled to release its results for the January-March quarter today.

Q4 Results Live: Sun Pharma shares drop 1% ahead of March quarter earnings

The shares of Sun Pharmaceutical Industries dropped over 1% to trade at Rs 1,712.90 apiece. The pharma company is scheduled to release its results for the January-March quarter today.

Q4 Results Live: What factors may impact ITC's earnings?

• Cigarette volumes: For the quarter ended March, cigarette volumes are likely to rise in the range of 2 to 6.5 percent, according to most brokerages. ITC is also seeing fierce competition from peers in this sector. "The cigarette business is expected to show stable volumes and pricing, with the portfolio continuing to grow, aided by improvements in the product mix," said Motilal Oswal.
• FMCG under pressure: The FMCG business is likely to see weak sales and margins in Q4FY25. Teh segment's EBITDA margins are likely to decrease sharply due to RM inflation in palm oil and wheat.
• Segments performance: The paper segment remained weak as an influx of cheap Chinese paper has prompted regional players to offer more discounts to customers. The FMCG business continues to see pressure in urban demand. The agriculture segment performed well during the quarter, added Motilal Oswal.
• Margins: EBITDA margin to contract due to the inflationary pressure related to the RM index of the cigarette and FMCG business and adverse business mix, i.e., higher salience from the agriculture segment. (Read more)

Q4 Results Live: What do brokerages estimate about ITC's March quarter earnings?

Here's a preview of ITC's March quarter earnings:

Earnings estimates of analysts polled by Moneycontrol are in a diverse range. The most optimistic estimate sees ITC’s net profit rising two percent year-on-year, while the most negative projection sees a fall of 7.6 percent in net profit for the quarter.

Q4 Results Live: ITC shares drop 2% ahead of March quarter earnings

The shares of ITC dropped nearly 2% to trade at Rs 425.15 apiece. The diversified FMCG-to-cigarettes conglomerate is scheduled to release its results for the January-March quarter today.

Q4 Results Live: ITC likely to report the highest revenue among all its listed peers

Diversified FMCG-to-cigarettes conglomerate ITC will report its earnings for the fourth quarter of the fiscal year 2025 on May 22, 2025. The FMCG player is likely to report the highest revenue among all its listed peers.

According to a Moneycontrol poll of nine brokerages, ITC is likely to report revenue of Rs 17,371 crore, rising 4.8 percent year-on-year compared to Rs 16,579 crore in the January to March quarter of FY24. However, it should be noted that the numbers are not strictly comparable. The March 2024 figures include the ITC Hotels numbers, which has now been spun-off into a separate entity. On a comparable basis, sales growth for the quarter should be between 6.5 to 8 percent, according to brokerages.

Net profit is likely to come in at Rs 4,906 crore in Q4FY25 as against Rs 5,022 crore in the year-ago period, a degrowth of 2.3 percent.